Shares of DBV Technologies SA – (NASDAQ:DBVT) saw an uptick in trading volume on Tuesday . 90,736 shares changed hands during trading, an increase of 27% from the previous session’s volume of 71,524 shares.The stock last traded at $34.98 and had previously closed at $34.56.

A number of brokerages have commented on DBVT. Jefferies Group reissued a “buy” rating on shares of DBV Technologies SA – in a report on Wednesday, June 8th. Zacks Investment Research lowered DBV Technologies SA – from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Finally, Leerink Swann reissued a “buy” rating and set a $54.00 price objective on shares of DBV Technologies SA – in a report on Tuesday. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $50.27.

The firm’s market capitalization is $1.59 billion. The stock’s 50-day moving average is $34.09 and its 200-day moving average is $31.63.

A number of hedge funds recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock valued at $26,208,000 after buying an additional 6,578 shares during the period. RS Investment Management Co. LLC raised its position in DBV Technologies SA – by 1.7% in the fourth quarter. RS Investment Management Co. LLC now owns 502,860 shares of the company’s stock valued at $18,259,000 after buying an additional 8,220 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in DBV Technologies SA – during the fourth quarter valued at about $2,551,000.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.